title: Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure?
abstract: In 1,009 patients with atrial fibrillation and congestive heart failure, the 2-year mortality rate was 31% in patients treated with rate control (n = 505) versus 29% in patients treated with rhythm control (n = 504). After adjusting for differences in baseline characteristics and medications, no significant difference in mortality was found between the 2 groups.
authors.affiliation: Duke Clinical Research Institute, 2400 Pratt Street, PO Box 17969, Durham, NC 27715, USA. alkha001@mc.duke.edu
authors.forename: Sana M
authors.initials: SM
authors.lastname: Al-Khatib
authors.forename: Linda K
authors.initials: LK
authors.lastname: Shaw
authors.forename: Kerry L
authors.initials: KL
authors.lastname: Lee
authors.forename: Christopher
authors.initials: C
authors.lastname: O'Connor
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000401:mortality / Q000517:prevention & control*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004077:Digoxin / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000150:complications* / Q000401:mortality; D006801:Humans; D008297:Male; D016016:Proportional Hazards Models; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D014859:Warfarin; D004077:Digoxin